HIV潜伏感染激活剂的研究进展
|
摘要
艾滋病是由人类免疫缺陷病毒(Human immunodeficiency virus,HIV)引起的人类最严重的单一病因疾病,以全身免疫系统严重损害为特征。高效抗逆转录病毒疗法(Highly active anti-retroviral therapy,HAART)的应用已经成功地将艾滋病从一种致死性疾病转变为慢性可控性疾病。但长期接受HAART治疗的艾滋病患者一旦停药,患者体内潜伏的HIV会迅速反弹。艾滋病无法彻底治愈的原因是患者体内HIV病毒潜伏储存库的存在。"Shock and kill"策略是使用HIV潜伏感染激活剂(Latency-reversing agents,LRAs)诱导潜伏HIV前病毒复制及表达,然后联合HAART将病毒一网打尽,同时由于细胞病变效应和/或HIV特征性免疫反应使潜伏细胞的半衰期大大缩短,最终达到功能性治愈的目的。因此,高效、安全且特异性促进潜伏库衰减的LRAs成为现今艾滋病治愈研究的热点。本文聚焦国内外前沿研究,对具有临床发展前景的HIV潜伏感染激活剂做一综述,为未来LRAs药物的研发指明方向。
Acquired immunodeficiency syndrome(AIDS)is one of the most serious diseases caused by infection with the human immunodeficiency virus(HIV).In AIDS,severe loss of the cellular immunity of the body occurs.Currently,the classification of AIDS has changed from a"fatal disease"to a"manageable chronic disease"by highly active antiretroviral therapy(HAART).HAART is long-term treatment of AIDS but,once it is withdrawn,the latent HIV in the body rebounds rapidly.Complete eradication of HIV with HAART does not seem to be possible because a stable reservoir of HIV latent infection is present in HIV-infected patients.One of the most challenging issues in HIV-1latent infection is how to kill the integrated previruses on the host target cells and diminish the HIV reservoir.A "shock and kill"strategy is to use latency-reversing agents(LRAs)to induce replication and expression of latent HIV,and then combinatorial HAART to kill the virus.Otherwise,because of cytopathic effects and/or characteristic HIV immune responses,the half-life of HIV latent cells will be reduced greatly.Therefore,LRAs with high efficiency,safety and specificity to promote the attenuation of latent libraries have become important in the research of a functional cure for HIV.This review introduces the latest research progress in LRA development.
Acquired immunodeficiency syndrome(AIDS)is one of the most serious diseases caused by infection with the human immunodeficiency virus(HIV).In AIDS,severe loss of the cellular immunity of the body occurs.Currently,the classification of AIDS has changed from a"fatal disease"to a"manageable chronic disease"by highly active antiretroviral therapy(HAART).HAART is long-term treatment of AIDS but,once it is withdrawn,the latent HIV in the body rebounds rapidly.Complete eradication of HIV with HAART does not seem to be possible because a stable reservoir of HIV latent infection is present in HIV-infected patients.One of the most challenging issues in HIV-1latent infection is how to kill the integrated previruses on the host target cells and diminish the HIV reservoir.A "shock and kill"strategy is to use latency-reversing agents(LRAs)to induce replication and expression of latent HIV,and then combinatorial HAART to kill the virus.Otherwise,because of cytopathic effects and/or characteristic HIV immune responses,the half-life of HIV latent cells will be reduced greatly.Therefore,LRAs with high efficiency,safety and specificity to promote the attenuation of latent libraries have become important in the research of a functional cure for HIV.This review introduces the latest research progress in LRA development.
引文
[1]ATC C.Life expectancy of individuals on combination antiretroviral therapy in high-income countries:a collaborative analysis of 14cohort studies[J].Lancet,2008,372(9635):293-299.
[2]Margolis D M,Garcia J V,Hazuda D J,Haynes B F.Latency reversal and viral clearance to cure HIV-1[J].Science,2016,353(6297):aaf6517.
[3]Deeks S G,Lewin S R,Havlir D V.The end of AIDS:HIV infection as a chronic disease[J].Lancet,2013,382(9903):1525-1533.
[4]Mellberg T,Gonzalez V D,Lindkvist A,Eden A,Sonnerborg A,Sandberg J K,Svennerholm B,Gisslen M.Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV[J].AIDS Res Ther,2011,8(20):21.
[5]Deeks S G,Lewin S R,Ross A L,Ananworanich J,Benkirane M,Cannon P,Chomont N,Douek D,Lifson J D,Lo YR,Kuritzkes D,Margolis D.International AIDS Society global scientific strategy:towards an HIV cure 2016[J].Nat Med,2016,22(8):839-850.
[6]Zerbato J M,Serrao E,Lenzi G,Kim B,Ambrose Z,Watkins SC,Engelman A N,Sluis-Cremer N.Establishment and Reversal of HIV-1 Latency in Naive and Central Memory CD4+T Cells In Vitro[J].J Virol,2016,90(18):8059-8073.
[7]de Masson A,Kirilovsky A,Zoorob R,Avettand-Fenoel V,Morin V,Oudin A,Descours B,Rouzioux C,Autran B.Blimp-1overexpression is associated with low HIV-1reservoir and transcription levels in central memory CD4+T cells from elite controllers[J].Aids,2014,28(11):1567-1577.
[8]Flynn J K,Paukovics G,Cashin K,Borm K,Ellett A,Roche M,Jakobsen M R,Churchill M J,Gorry P R.Quantifying susceptibility of CD4+stem memory Tcells to infection by laboratory adapted and clinical HIV-1strains[J].Viruses,2014,6(2):709-726.
[9]Finzi D,Blankson J,Siliciano J D,Margolick J B,Chadwick K,Pierson T,Smith K,Lisziewicz J,Lori F,Flexner C,Quinn TC,Chaisson RE,Rosenberg E,Walker B,Gange S,Gallant J,Siliciano RF.Latent infection of CD4+T cells provides a mechanism for lifelong persistence of HIV-1,even in patients on effective combination therapy[J].Nat Med,1999,5(5):512-517.
[10]Arenaccio C,Anticoli S,Manfredi F,Chiozzini C,Olivetta E,Federico M.Latent HIV-1is activated by exosomes from cells infected with either replication-competent or defective HIV-1[J].Retrovirology,2015,12(1):87.
[11]Tripathy M K,McManamy M E,Burch B D,Archin N M,Margolis D M.H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+T Cells[J].J Virol,2015,89(16):8392-8405.
[12]van der Sluis R M,Jeeninga R E,Berkhout B.Establishment and molecular mechanisms of HIV-1latency in T cells[J].Curr Opin Virol,2013,3(6):700-706.
[13]Hutter G,Nowak D,Mossner M,Ganepola S,Mussig A,Allers K,Schneider T,Hofmann J,Kucherer C,Blau O,Blau I W,Hofmann W K,Thiel E.Longterm control of HIV by CCR5 Delta32/Delta32stemcell transplantation[J].N Engl J Med,2009,360(7):692-698.
[14]Henrich T J,Hanhauser E,Harrison L J,Palmer C D,Romero-Tejeda M,Jost S,Bosch R J,Kuritzkes D R.CCR5-Delta32 Heterozygosity,HIV-1 Reservoir Size,and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy[J].J Infect Dis,2016,213(5):766-770.
[15]Darcis G,Van Driessche B,Van Lint C.Preclinical shock strategies to reactivate latent HIV-1:an update[J].Curr Opin HIV AIDS,2016,11(4):388-393.
[16]Trono D,Van Lint C,Rouzioux C,Verdin E,BarreSinoussi F,Chun T W,Chomont N.HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals[J].Science,2010,329(5988):174-180.
[17]Hocqueloux L,Prazuck T,Avettand-Fenoel V,Lafeuillade A,Cardon B,Viard J P,Rouzioux C.Longterm immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1infection[J].Aids,2010,24(10):1598-1601.
[18]Persaud D,Gay H,Ziemniak C,Chen Y H,Piatak M,Jr.,Chun T W,Strain M,Richman D,Luzuriaga K.Absence of detectable HIV-1viremia after treatment cessation in an infant[J].N Engl J Med,2013,369(19):1828-1835.
[19]Lampton L M.Functional HIV cure achieved in Mississippi[J].J Miss State Med Assoc,2013,54(4):94.
[20]Yukl S A,Shergill A K,McQuaid K,Gianella S,Lampiris H,Hare C B,Pandori M,Sinclair E,Gunthard H F,Fischer M,Wong J K,Havlir D V.Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy[J].Aids,2010,24(16):2451-2460.
[21]Yilmaz A,Verhofstede C,D'Avolio A,Watson V,Hagberg L,Fuchs D,Svennerholm B,Gisslen M.Treatment intensification has no effect on the HIV-1central nervous system infection in patients on suppressive antiretroviral therapy[J].J Acquir Immune Defic Syndr,2010,55(5):590-596.
[22]Wayengera M.Proviral HIV-genome-wide and polgene specific zinc finger nucleases:usability for targeted HIV gene therapy[J].Theor Biol Med Model,2011,8(1):26.
[23]Qu X,Wang P,Ding D,Wang X,Zhang G,Zhou X,Liu L,Zhu X,Zeng H,Zhu H.Zinc finger nuclease:a new approach for excising HIV-1proviral DNA from infected human T cells[J].Mol Biol Rep,2014,41(9):5819-5827.
[24]Strong C L,Guerra H P,Mathew K R,Roy N,Simpson L R,Schiller M R.Damaging the Integrated HIV Proviral DNA with TALENs[J].PLoS One,2015,10(5):e0125652.
[25]Wang G,Zhao N,Berkhout B,Das A T.A Combinatorial CRISPR-Cas9 Attack on HIV-1DNA Extinguishes All Infectious Provirus in Infected T Cell Cultures[J].Cell Rep,2016,17(11):2819-2826.
[26]Hu W,Kaminski R,Yang F,Zhang Y,Cosentino L,Li F,Luo B,Alvarez-Carbonell D,Garcia-Mesa Y,Karn J,Mo X,Khalili K.RNA-directed gene editing specifically eradicates latent and prevents new HIV-1infection[J].Proc Natl Acad Sci U S A,2014,111(31):11461-11466.
[27]Mussolino C,Morbitzer R,Lutge F,Dannemann N,Lahaye T,Cathomen T.A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity[J].Nucleic Acids Res,2011,39(21):9283-9293.
[28]Ye L,Wang J,Beyer A I,Teque F,Cradick T J,Qi Z,Chang J C,Bao G,Muench M O,Yu J,Levy J A,Kan Y W.Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Delta32mutation confers resistance to HIV infection[J].Proc Natl Acad Sci U S A,2014,111(26):9591-9596.
[29]Tebas P,Stein D,Tang W W,Frank I,Wang S Q,Lee G,Spratt S K,Surosky R T,Giedlin M A,Nichol G,Holmes M C,Gregory P D,Ando D G,Kalos M,Collman R G,Binder-Scholl G,Plesa G,Hwang W T,Levine B L,June C H.Gene editing of CCR5in autologous CD4Tcells of persons infected with HIV[J].N Engl J Med,2014,370(10):901-910.
[30]Telenti A.Safety concerns about CCR5as an antiviral target[J].Curr Opin HIV AIDS,2009,4(2):131-135.
[31]Emmelkamp J M,Rockstroh J K.CCR5antagonists:comparison of efficacy,side effects,pharmacokinetics and interactions--review of the literature[J].Eur J Med Res,2007,12(9):409-417.
[32]Deeks SG.HIV:Shock and kill[J].Nature,2012,487(7408):439-440.
[33]Wang Z,Zang C,Cui K,Schones D E,Barski A,Peng W,Zhao K.Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes[J].Cell,2009,138(5):1019-1031.
[34]Archin N M,Espeseth A,Parker D,Cheema M,Hazuda D,Margolis D M.Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid[J].AIDS Res Hum Retroviruses,2009,25(2):207-212.
[35]Bouchat S,Gatot JS,Kabeya K,Cardona C,Colin L,Herbein G,De Wit S,Clumeck N,Lambotte O,Rouzioux C,Rohr O,Van Lint C.Histone methyltransferase inhibitors induce HIV-1recovery in resting CD4(+)T cells from HIV-1-infected HAART-treated patients[J].Aids,2012,26(12):1473-1482.
[36]Delagreverie H M,Delaugerre C,Lewin S R,Deeks S G,Li J Z.Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents[J].Open Forum Infect Dis,2016,3(4):ofw189.
[37]Kogge A,Volteau C,Saint-Jean M,Peuvrel L,Brocard A,Knol AC,Renaut JJ,Dreno B,Quereux G.Vorinostat for refractory or relapsing epidermotropic T-cell lymphoma:a retrospective cohort study of 15patients[J].Acta Derm Venereol,2015,95(1):72-77.
[38]Archin N M,Liberty A L,Kashuba A D,Choudhary S K,Kuruc J D,Crooks A M,Parker D C,Anderson E M,Kearney M F,Strain M C,Richman D D,Hudgens M G,Bosch R J,Coffin J M,Eron J J,Hazuda D J,Margolis D M.Administration of vorinostat disrupts HIV-1latency in patients on antiretroviral therapy[J].Nature,2012,487(7408):482-485.
[39]Prince H M,Bishton M J,Johnstone R W.Panobinostat(LBH589):apotent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors[J].Future Oncol,2009,5(5):601-612.
[40]Rasmussen T A,Schmeltz Sogaard O,Brinkmann C,Wightman F,Lewin S R,Melchjorsen J,Dinarello C,Ostergaard L,Tolstrup M.Comparison of HDAC inhibitors in clinical development:effect on HIV production in latently infected cells and T-cell activation[J].Hum Vaccin Immunother,2013,9(5):993-1001.
[41]Tsai P,Wu G,Baker C E,Thayer W O,Spagnuolo R A,Sanchez R,Barrett S,Howell B,Margolis D,Hazuda D J,Archin N M,Garcia J V.In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection[J].Retrovirology,2016,13(1):36.
[42]Olesen R,Vigano S,Rasmussen T A,Sogaard O S,Ouyang Z,Buzon M,Bashirova A,Carrington M,Palmer S,Brinkmann C R,Yu X G,Ostergaard L,Tolstrup M,Lichterfeld M.Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat[J].J Virol,2015,89(20):10176-10189.
[43]Wei D G,Chiang V,Fyne E,Balakrishnan M,Barnes T,Graupe M,Hesselgesser J,Irrinki A,Murry J P,Stepan G,Stray K M,Tsai A,Yu H,Spindler J,Kearney M,Spina C A,McMahon D,Lalezari J,Sloan D,Mellors J,Geleziunas R,Cihlar T.Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 Tcells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing[J/OL].PLoS Pathog,2014,10(4):e1004071.
[44]Sogaard O S,Graversen M E,Leth S,Olesen R,Brinkmann C R,Nissen S K,Kjaer A S,Schleimann M H,Denton P W,Hey-Cunningham W J,Koelsch K K,Pantaleo G,Krogsgaard K,Sommerfelt M,Fromentin R,Chomont N,Rasmussen T A,Ostergaard L,Tolstrup M.The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo[J/OL].PLoS Pathog,2015,11(9):e1005142.
[45]Hezareh M,Moukil M A,Szanto I,Pondarzewski M,Mouche S,Cherix N,Brown S J,Carpentier J L,Foti M.Mechanisms of HIV receptor and co-receptor down-regulation by prostratin:role of conventional and novel PKC isoforms[J].Antivir Chem Chemother,2004,15(4):207-222.
[46]Williams S A,Kwon H,Chen L F,Greene W C.Sustained induction of NF-kappa B is required for efficient expression of latent human immunodeficiency virus type 1[J].J Virol,2007,81(11):6043-6056.
[47]Cary D C,Fujinaga K,Peterlin B M.Molecular mechanisms of HIV latency[J].J Clin Invest,2016,126(2):448-454.
[48]Fernandez G,Zaikos T D,Khan S Z,Jacobi A M,Behlke M A,Zeichner S L.Targeting IkappaB proteins for HIV latency activation:the role of individual IkappaB and NF-kappaB proteins[J].J Virol,2013,87(7):3966-3978.
[49]Miana G A,Riaz M,Shahzad-ul-Hussan S,Paracha R Z,Paracha U Z.Prostratin:An Overview[J].Mini Rev Med Chem,2015,15(13):1122-1130.
[50]Korin Y D,Brooks D G,Brown S,Korotzer A,Zack J A.Effects of prostratin on T-cell activation and human immunodeficiency virus latency[J].J Virol,2002,76(16):8118-8123.
[51]Williams S A,Chen L F,Kwon H,Fenard D,Bisgrove D,Verdin E,Greene W C.Prostratin antagonizes HIV latency by activating NF-kappaB[J].J Biol Chem,2004,279(40):42008-42017.
[52]Wender P A,Kee J M,Warrington J M.Practical synthesis of prostratin,DPP,and their analogs,adjuvant leads against latent HIV[J].Science,2008,320(5876):649-652.
[53]Walker-Sperling V E,Pohlmeyer C W,Tarwater P M,Blankson J N.The Effect of Latency Reversal Agents on Primary CD8+T Cells:Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication[J].E Bio Medicine,2016,8(1):217-229.
[54]Dental C,Proust A.HIV-1Latency-Reversing Agents Prostratin and Bryostatin-1Induce Blood-Brain Barrier Disruption/Inflammation and Modulate Leukocyte Adhesion/Transmigration[J].J Immunol,2017,198(3):1229-1241.
[55]Diaz L,Martinez-Bonet M,Sanchez J,FernandezPineda A,Jimenez J L,Munoz E,Moreno S,Alvarez S,Munoz-Fernandez M A.Bryostatin activates HIV-1latent expression in human astrocytes through a PKC and NF-kB-dependent mechanism[J].Sci Rep,2015,5(1):12442.
[56]Nelson T J,Sen A,Alkon D L,Sun M K.Adduct formation in liquid chromatography-triple quadrupole mass spectrometric measurement of bryostatin 1[J].J Chromatogr B Analyt Technol Biomed Life Sci,2014,944:55-62.
[57]Liu P,Xiang Y,Fujinaga K,Bartholomeeusen K,Nilson K A,Price D H,Peterlin B M.Release of positive transcription elongation factor b(P-TEFb)from 7SK small nuclear ribonucleoprotein(snRNP)activates hexamethylene bisacetamide-inducible protein(HEXIM1)transcription[J].J Biol Chem,2014,289(14):9918-9925.
[58]Tahirov T H,Babayeva N D,Varzavand K,Cooper J J,Sedore S C,Price D H.Crystal structure of HIV-1Tat complexed with human P-TEFb[J].Nature,2010,465(7299):747-751.
[59]Contreras X,Barboric M,Lenasi T,Peterlin B M.HMBA releases P-TEFb from HEXIM1and 7SK snRNA via PI3K/Akt and activates HIV transcription[J].PLoS Pathog,2007,3(10):1459-1469.
[60]Chen D,Wang H,Aweya J J,Chen Y,Chen M,Wu X,Chen X,Lu J,Chen R.HMBA Enhances Prostratin-Induced Activation of Latent HIV-1via Suppressing the Expression of Negative Feedback Regulator A20/TNFAIP3in NF-kappaB Signaling[J].Biomed Res Int,2016,2016(1):5173205.
[61]Choudhary S K,Archin N M,Margolis D M.Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1latency in CD4(+)T cells[J].J Infect Dis,2008,197(8):1162-1170.
[62]Zhu J,Gaiha G D,John S P,Pertel T,Chin C R,Gao G,Qu H,Walker B D,Elledge S J,Brass A L.Reactivation of latent HIV-1by inhibition of BRD4[J].Cell Rep,2012,2(4):807-816.
[63]Bartholomeeusen K,Xiang Y,Fujinaga K,Peterlin B M.Bromodomain and extra-terminal(BET)bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b(PTEFb)from 7SK small nuclear ribonucleoprotein[J].J Biol Chem,2012,287(43):36609-36616.
[64]Boehm D,Calvanese V,Dar R D,Xing S,Schroeder S,Martins L,Aull K,Li P C,Planelles V,Bradner J E,Zhou M M,Siliciano R F,Weinberger L,Verdin E,Ott M.BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism[J].Cell Cycle,2013,12(3):452-462.
[65]Li Z,Guo J,Wu Y,Zhou Q.The BET bromodomain inhibitor JQ1activates HIV latency through antagonizing Brd4inhibition of Tat-transactivation[J].Nucleic Acids Res,2013,41(1):277-287.
[66]Banerjee C,Archin N,Michaels D,Belkina A C,Denis G V,Bradner J,Sebastiani P,Margolis D M,Montano M.BET bromodomain inhibition as a novel strategy for reactivation of HIV-1[J].J Leukoc Biol,2012,92(6):1147-1154.
[67]Lee D U,Katavolos P,Palanisamy G,Katewa A,Sioson C,Corpuz J,Pang J,DeMent K,Choo E,Ghilardi N,Diaz D,Danilenko D M.Nonselective inhibition of the epigenetic transcriptional regulator BET induces marked lymphoid and hematopoietic toxicity in mice[J].Toxicol Appl Pharmacol,2016,300(1):47-54.
[68]Gaudio E,Tarantelli C,Ponzoni M,Odore E,Rezai K,Bernasconi E,Cascione L,Rinaldi A,Stathis A,Riveiro E,Cvitkovic E,Zucca E,Bertoni F.Bromodomain inhibitor OTX015(MK-8628)combined with targeted agents shows strong in vivo antitumor activity in lymphoma[J].Oncotarget,2016,7(36):58142-58147.
[69]Lu P,Qu X,Shen Y,Jiang Z,Wang P,Zeng H,Ji H,Deng J,Yang X,Li X,Lu H,Zhu H.The BET inhibitor OTX015reactivates latent HIV-1through PTEFb[J].Sci Rep,2016,6(1):24100.
[70]Bouchat S,Delacourt N,Kula A,Darcis G,Van Driessche B,Corazza F,Gatot JS,Melard A,Vanhulle C,Kabeya K,Pardons M,Avettand-Fenoel V,Clumeck N,De Wit S,Rohr O,Rouzioux C,Van Lint C.Sequential treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1[J].EMBO Mol Med,2015,8(2):117-138.
[71]Clouser C L,Bonnac L,Mansky L M,Patterson S E.Characterization of permeability,stability and antiHIV-1activity of decitabine and gemcitabine divalerate prodrugs[J].Antivir Chem Chemother,2014,23(6):223-230.
[72]Fernandez G,Zeichner S L.Cell line-dependent variability in HIV activation employing DNMT inhibitors[J].Virol J,2010,7(1):266.
[73]Rawson J M,Daly M B,Xie J,Clouser C L,Landman S R,Reilly C S,Bonnac L,Kim B,Patterson S E,Mansky L M.5-Azacytidine Enhances the Mutagenesis of HIV-1by Reduction to 5-Aza-2'-Deoxycytidine[J].Antimicrob Agents Chemother,2016,60(4):2318-2325.
[74]Ding D,Qu X,Li L,Zhou X,Liu S,Lin S,Wang P,Liu S,Kong C,Wang X,Liu L,Zhu H.Involvement of histone methyltransferase GLP in HIV-1latency through catalysis of H3K9dimethylation[J].Virology,2013,440(2):182-189.
[75]Verma M.Epigenetic regulation of HIV,AIDS,and AIDS-related malignancies[J].Methods Mol Biol,2015,1238(1):381-403.
[76]Levy Y,Sereti I,Tambussi G,Routy J P,Lelievre J D,Delfraissy J F,Molina J M,Fischl M,Goujard C,Rodriguez B,Rouzioux C,Avettand-Fenoel V,Croughs T,Beq S,Morre M,Poulin J F,Sekaly R P,Thiebaut R,Lederman M M.Effects of recombinant human interleukin 7on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy:results of a phase I/IIa randomized,placebocontrolled,multicenter study[J].Clin Infect Dis,2012,55(2):291-300.
[77]Nunnari G,Pomerantz R J.IL-7as a potential therapy for HIV-1-infected individuals[J].Expert Opin Biol Ther,2005,5(11):1421-1426.
[78]Wang F X,Xu Y,Sullivan J,Souder E,Argyris E G,Acheampong E A,Fisher J,Sierra M,Thomson M M,Najera R,Frank I,Kulkosky J,Pomerantz R J,Nunnari G.IL-7is a potent and proviral strain-specific inducer of latent HIV-1cellular reservoirs of infected individuals on virally suppressive HAART[J].J Clin Invest,2005,115(1):128-137.
[79]Stellbrink H J,van Lunzen J,Westby M,O'Sullivan E,Schneider C,Adam A,Weitner L,Kuhlmann B,Hoffmann C,Fenske S,Aries P S,Degen O,Eggers C,Petersen H,Haag F,Horst H A,Dalhoff K,Mocklinghoff C,Cammack N,Tenner-Racz K,Racz P.Effects of interleukin-2plus highly active antiretroviral therapy on HIV-1replication and proviral DNA(COSMIC trial)[J].AIDS,2002,16(11):1479-1487.
[80]Badia R,Pujantell M,Riveira-Munoz E,Puig T,Torres-Torronteras J,Marti R,Clotet B,Ampudia RM,Vives-Pi M.The G1/S Specific Cyclin D2Is a Regulator of HIV-1 Restriction in Non-proliferating Cells[J/OL].PLoS Pathog,2016,12(8):e1005829.
[81]Xing S,Bullen C K,Shroff N S,Shan L,Yang H C,Manucci J L,Bhat S,Zhang H,Margolick J B,Quinn T C,Margolis D M,Siliciano J D,Siliciano R F.Disulfiram reactivates latent HIV-1in a Bcl-2-transduced primary CD4+T cell model without inducing global T cell activation[J].J Virol,2011,85(12):6060-6064.
[82]Doyon G,Zerbato J,Mellors J W,Sluis-Cremer N.Disulfiram reactivates latent HIV-1expression through depletion of the phosphatase and tensin homolog[J].Aids,2013,27(2):F7-f11.
[83]Elliott J H,McMahon J H,Chang C C,Lee S A,Hartogensis W,Bumpus N,Savic R,Roney J,Hoh R,Solomon A,Piatak M,Gorelick R J,Lifson J,Bacchetti P,Deeks S G,Lewin S R.Short-term administration of disulfiram for reversal of latent HIV infection:aphase 2dose-escalation study[J/OL].Lancet HIV,2015,2(12):e520-529.
[84]Spivak A M,Andrade A,Eisele E,Hoh R,Bacchetti P,Bumpus N N,Emad F,Buckheit R,3rd,McCanceKatz E F,Lai J,Kennedy M,Chander G,Siliciano R F,Siliciano J D,Deeks S G.A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy[J].Clin Infect Dis,2014,58(6):883-890.
[85]Li P,Kaiser P,Lampiris H W,Kim P,Yukl S A,Havlir D V,Greene W C,Wong J K.Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation[J].Nat Med,2016,22(7):807-811.
[86]Gallo R C.Shock and kill with caution[J].Science,2016,354(6309):177-178.
[2]Margolis D M,Garcia J V,Hazuda D J,Haynes B F.Latency reversal and viral clearance to cure HIV-1[J].Science,2016,353(6297):aaf6517.
[3]Deeks S G,Lewin S R,Havlir D V.The end of AIDS:HIV infection as a chronic disease[J].Lancet,2013,382(9903):1525-1533.
[4]Mellberg T,Gonzalez V D,Lindkvist A,Eden A,Sonnerborg A,Sandberg J K,Svennerholm B,Gisslen M.Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV[J].AIDS Res Ther,2011,8(20):21.
[5]Deeks S G,Lewin S R,Ross A L,Ananworanich J,Benkirane M,Cannon P,Chomont N,Douek D,Lifson J D,Lo YR,Kuritzkes D,Margolis D.International AIDS Society global scientific strategy:towards an HIV cure 2016[J].Nat Med,2016,22(8):839-850.
[6]Zerbato J M,Serrao E,Lenzi G,Kim B,Ambrose Z,Watkins SC,Engelman A N,Sluis-Cremer N.Establishment and Reversal of HIV-1 Latency in Naive and Central Memory CD4+T Cells In Vitro[J].J Virol,2016,90(18):8059-8073.
[7]de Masson A,Kirilovsky A,Zoorob R,Avettand-Fenoel V,Morin V,Oudin A,Descours B,Rouzioux C,Autran B.Blimp-1overexpression is associated with low HIV-1reservoir and transcription levels in central memory CD4+T cells from elite controllers[J].Aids,2014,28(11):1567-1577.
[8]Flynn J K,Paukovics G,Cashin K,Borm K,Ellett A,Roche M,Jakobsen M R,Churchill M J,Gorry P R.Quantifying susceptibility of CD4+stem memory Tcells to infection by laboratory adapted and clinical HIV-1strains[J].Viruses,2014,6(2):709-726.
[9]Finzi D,Blankson J,Siliciano J D,Margolick J B,Chadwick K,Pierson T,Smith K,Lisziewicz J,Lori F,Flexner C,Quinn TC,Chaisson RE,Rosenberg E,Walker B,Gange S,Gallant J,Siliciano RF.Latent infection of CD4+T cells provides a mechanism for lifelong persistence of HIV-1,even in patients on effective combination therapy[J].Nat Med,1999,5(5):512-517.
[10]Arenaccio C,Anticoli S,Manfredi F,Chiozzini C,Olivetta E,Federico M.Latent HIV-1is activated by exosomes from cells infected with either replication-competent or defective HIV-1[J].Retrovirology,2015,12(1):87.
[11]Tripathy M K,McManamy M E,Burch B D,Archin N M,Margolis D M.H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+T Cells[J].J Virol,2015,89(16):8392-8405.
[12]van der Sluis R M,Jeeninga R E,Berkhout B.Establishment and molecular mechanisms of HIV-1latency in T cells[J].Curr Opin Virol,2013,3(6):700-706.
[13]Hutter G,Nowak D,Mossner M,Ganepola S,Mussig A,Allers K,Schneider T,Hofmann J,Kucherer C,Blau O,Blau I W,Hofmann W K,Thiel E.Longterm control of HIV by CCR5 Delta32/Delta32stemcell transplantation[J].N Engl J Med,2009,360(7):692-698.
[14]Henrich T J,Hanhauser E,Harrison L J,Palmer C D,Romero-Tejeda M,Jost S,Bosch R J,Kuritzkes D R.CCR5-Delta32 Heterozygosity,HIV-1 Reservoir Size,and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy[J].J Infect Dis,2016,213(5):766-770.
[15]Darcis G,Van Driessche B,Van Lint C.Preclinical shock strategies to reactivate latent HIV-1:an update[J].Curr Opin HIV AIDS,2016,11(4):388-393.
[16]Trono D,Van Lint C,Rouzioux C,Verdin E,BarreSinoussi F,Chun T W,Chomont N.HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals[J].Science,2010,329(5988):174-180.
[17]Hocqueloux L,Prazuck T,Avettand-Fenoel V,Lafeuillade A,Cardon B,Viard J P,Rouzioux C.Longterm immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1infection[J].Aids,2010,24(10):1598-1601.
[18]Persaud D,Gay H,Ziemniak C,Chen Y H,Piatak M,Jr.,Chun T W,Strain M,Richman D,Luzuriaga K.Absence of detectable HIV-1viremia after treatment cessation in an infant[J].N Engl J Med,2013,369(19):1828-1835.
[19]Lampton L M.Functional HIV cure achieved in Mississippi[J].J Miss State Med Assoc,2013,54(4):94.
[20]Yukl S A,Shergill A K,McQuaid K,Gianella S,Lampiris H,Hare C B,Pandori M,Sinclair E,Gunthard H F,Fischer M,Wong J K,Havlir D V.Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy[J].Aids,2010,24(16):2451-2460.
[21]Yilmaz A,Verhofstede C,D'Avolio A,Watson V,Hagberg L,Fuchs D,Svennerholm B,Gisslen M.Treatment intensification has no effect on the HIV-1central nervous system infection in patients on suppressive antiretroviral therapy[J].J Acquir Immune Defic Syndr,2010,55(5):590-596.
[22]Wayengera M.Proviral HIV-genome-wide and polgene specific zinc finger nucleases:usability for targeted HIV gene therapy[J].Theor Biol Med Model,2011,8(1):26.
[23]Qu X,Wang P,Ding D,Wang X,Zhang G,Zhou X,Liu L,Zhu X,Zeng H,Zhu H.Zinc finger nuclease:a new approach for excising HIV-1proviral DNA from infected human T cells[J].Mol Biol Rep,2014,41(9):5819-5827.
[24]Strong C L,Guerra H P,Mathew K R,Roy N,Simpson L R,Schiller M R.Damaging the Integrated HIV Proviral DNA with TALENs[J].PLoS One,2015,10(5):e0125652.
[25]Wang G,Zhao N,Berkhout B,Das A T.A Combinatorial CRISPR-Cas9 Attack on HIV-1DNA Extinguishes All Infectious Provirus in Infected T Cell Cultures[J].Cell Rep,2016,17(11):2819-2826.
[26]Hu W,Kaminski R,Yang F,Zhang Y,Cosentino L,Li F,Luo B,Alvarez-Carbonell D,Garcia-Mesa Y,Karn J,Mo X,Khalili K.RNA-directed gene editing specifically eradicates latent and prevents new HIV-1infection[J].Proc Natl Acad Sci U S A,2014,111(31):11461-11466.
[27]Mussolino C,Morbitzer R,Lutge F,Dannemann N,Lahaye T,Cathomen T.A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity[J].Nucleic Acids Res,2011,39(21):9283-9293.
[28]Ye L,Wang J,Beyer A I,Teque F,Cradick T J,Qi Z,Chang J C,Bao G,Muench M O,Yu J,Levy J A,Kan Y W.Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Delta32mutation confers resistance to HIV infection[J].Proc Natl Acad Sci U S A,2014,111(26):9591-9596.
[29]Tebas P,Stein D,Tang W W,Frank I,Wang S Q,Lee G,Spratt S K,Surosky R T,Giedlin M A,Nichol G,Holmes M C,Gregory P D,Ando D G,Kalos M,Collman R G,Binder-Scholl G,Plesa G,Hwang W T,Levine B L,June C H.Gene editing of CCR5in autologous CD4Tcells of persons infected with HIV[J].N Engl J Med,2014,370(10):901-910.
[30]Telenti A.Safety concerns about CCR5as an antiviral target[J].Curr Opin HIV AIDS,2009,4(2):131-135.
[31]Emmelkamp J M,Rockstroh J K.CCR5antagonists:comparison of efficacy,side effects,pharmacokinetics and interactions--review of the literature[J].Eur J Med Res,2007,12(9):409-417.
[32]Deeks SG.HIV:Shock and kill[J].Nature,2012,487(7408):439-440.
[33]Wang Z,Zang C,Cui K,Schones D E,Barski A,Peng W,Zhao K.Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes[J].Cell,2009,138(5):1019-1031.
[34]Archin N M,Espeseth A,Parker D,Cheema M,Hazuda D,Margolis D M.Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid[J].AIDS Res Hum Retroviruses,2009,25(2):207-212.
[35]Bouchat S,Gatot JS,Kabeya K,Cardona C,Colin L,Herbein G,De Wit S,Clumeck N,Lambotte O,Rouzioux C,Rohr O,Van Lint C.Histone methyltransferase inhibitors induce HIV-1recovery in resting CD4(+)T cells from HIV-1-infected HAART-treated patients[J].Aids,2012,26(12):1473-1482.
[36]Delagreverie H M,Delaugerre C,Lewin S R,Deeks S G,Li J Z.Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents[J].Open Forum Infect Dis,2016,3(4):ofw189.
[37]Kogge A,Volteau C,Saint-Jean M,Peuvrel L,Brocard A,Knol AC,Renaut JJ,Dreno B,Quereux G.Vorinostat for refractory or relapsing epidermotropic T-cell lymphoma:a retrospective cohort study of 15patients[J].Acta Derm Venereol,2015,95(1):72-77.
[38]Archin N M,Liberty A L,Kashuba A D,Choudhary S K,Kuruc J D,Crooks A M,Parker D C,Anderson E M,Kearney M F,Strain M C,Richman D D,Hudgens M G,Bosch R J,Coffin J M,Eron J J,Hazuda D J,Margolis D M.Administration of vorinostat disrupts HIV-1latency in patients on antiretroviral therapy[J].Nature,2012,487(7408):482-485.
[39]Prince H M,Bishton M J,Johnstone R W.Panobinostat(LBH589):apotent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors[J].Future Oncol,2009,5(5):601-612.
[40]Rasmussen T A,Schmeltz Sogaard O,Brinkmann C,Wightman F,Lewin S R,Melchjorsen J,Dinarello C,Ostergaard L,Tolstrup M.Comparison of HDAC inhibitors in clinical development:effect on HIV production in latently infected cells and T-cell activation[J].Hum Vaccin Immunother,2013,9(5):993-1001.
[41]Tsai P,Wu G,Baker C E,Thayer W O,Spagnuolo R A,Sanchez R,Barrett S,Howell B,Margolis D,Hazuda D J,Archin N M,Garcia J V.In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection[J].Retrovirology,2016,13(1):36.
[42]Olesen R,Vigano S,Rasmussen T A,Sogaard O S,Ouyang Z,Buzon M,Bashirova A,Carrington M,Palmer S,Brinkmann C R,Yu X G,Ostergaard L,Tolstrup M,Lichterfeld M.Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat[J].J Virol,2015,89(20):10176-10189.
[43]Wei D G,Chiang V,Fyne E,Balakrishnan M,Barnes T,Graupe M,Hesselgesser J,Irrinki A,Murry J P,Stepan G,Stray K M,Tsai A,Yu H,Spindler J,Kearney M,Spina C A,McMahon D,Lalezari J,Sloan D,Mellors J,Geleziunas R,Cihlar T.Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 Tcells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing[J/OL].PLoS Pathog,2014,10(4):e1004071.
[44]Sogaard O S,Graversen M E,Leth S,Olesen R,Brinkmann C R,Nissen S K,Kjaer A S,Schleimann M H,Denton P W,Hey-Cunningham W J,Koelsch K K,Pantaleo G,Krogsgaard K,Sommerfelt M,Fromentin R,Chomont N,Rasmussen T A,Ostergaard L,Tolstrup M.The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo[J/OL].PLoS Pathog,2015,11(9):e1005142.
[45]Hezareh M,Moukil M A,Szanto I,Pondarzewski M,Mouche S,Cherix N,Brown S J,Carpentier J L,Foti M.Mechanisms of HIV receptor and co-receptor down-regulation by prostratin:role of conventional and novel PKC isoforms[J].Antivir Chem Chemother,2004,15(4):207-222.
[46]Williams S A,Kwon H,Chen L F,Greene W C.Sustained induction of NF-kappa B is required for efficient expression of latent human immunodeficiency virus type 1[J].J Virol,2007,81(11):6043-6056.
[47]Cary D C,Fujinaga K,Peterlin B M.Molecular mechanisms of HIV latency[J].J Clin Invest,2016,126(2):448-454.
[48]Fernandez G,Zaikos T D,Khan S Z,Jacobi A M,Behlke M A,Zeichner S L.Targeting IkappaB proteins for HIV latency activation:the role of individual IkappaB and NF-kappaB proteins[J].J Virol,2013,87(7):3966-3978.
[49]Miana G A,Riaz M,Shahzad-ul-Hussan S,Paracha R Z,Paracha U Z.Prostratin:An Overview[J].Mini Rev Med Chem,2015,15(13):1122-1130.
[50]Korin Y D,Brooks D G,Brown S,Korotzer A,Zack J A.Effects of prostratin on T-cell activation and human immunodeficiency virus latency[J].J Virol,2002,76(16):8118-8123.
[51]Williams S A,Chen L F,Kwon H,Fenard D,Bisgrove D,Verdin E,Greene W C.Prostratin antagonizes HIV latency by activating NF-kappaB[J].J Biol Chem,2004,279(40):42008-42017.
[52]Wender P A,Kee J M,Warrington J M.Practical synthesis of prostratin,DPP,and their analogs,adjuvant leads against latent HIV[J].Science,2008,320(5876):649-652.
[53]Walker-Sperling V E,Pohlmeyer C W,Tarwater P M,Blankson J N.The Effect of Latency Reversal Agents on Primary CD8+T Cells:Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication[J].E Bio Medicine,2016,8(1):217-229.
[54]Dental C,Proust A.HIV-1Latency-Reversing Agents Prostratin and Bryostatin-1Induce Blood-Brain Barrier Disruption/Inflammation and Modulate Leukocyte Adhesion/Transmigration[J].J Immunol,2017,198(3):1229-1241.
[55]Diaz L,Martinez-Bonet M,Sanchez J,FernandezPineda A,Jimenez J L,Munoz E,Moreno S,Alvarez S,Munoz-Fernandez M A.Bryostatin activates HIV-1latent expression in human astrocytes through a PKC and NF-kB-dependent mechanism[J].Sci Rep,2015,5(1):12442.
[56]Nelson T J,Sen A,Alkon D L,Sun M K.Adduct formation in liquid chromatography-triple quadrupole mass spectrometric measurement of bryostatin 1[J].J Chromatogr B Analyt Technol Biomed Life Sci,2014,944:55-62.
[57]Liu P,Xiang Y,Fujinaga K,Bartholomeeusen K,Nilson K A,Price D H,Peterlin B M.Release of positive transcription elongation factor b(P-TEFb)from 7SK small nuclear ribonucleoprotein(snRNP)activates hexamethylene bisacetamide-inducible protein(HEXIM1)transcription[J].J Biol Chem,2014,289(14):9918-9925.
[58]Tahirov T H,Babayeva N D,Varzavand K,Cooper J J,Sedore S C,Price D H.Crystal structure of HIV-1Tat complexed with human P-TEFb[J].Nature,2010,465(7299):747-751.
[59]Contreras X,Barboric M,Lenasi T,Peterlin B M.HMBA releases P-TEFb from HEXIM1and 7SK snRNA via PI3K/Akt and activates HIV transcription[J].PLoS Pathog,2007,3(10):1459-1469.
[60]Chen D,Wang H,Aweya J J,Chen Y,Chen M,Wu X,Chen X,Lu J,Chen R.HMBA Enhances Prostratin-Induced Activation of Latent HIV-1via Suppressing the Expression of Negative Feedback Regulator A20/TNFAIP3in NF-kappaB Signaling[J].Biomed Res Int,2016,2016(1):5173205.
[61]Choudhary S K,Archin N M,Margolis D M.Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1latency in CD4(+)T cells[J].J Infect Dis,2008,197(8):1162-1170.
[62]Zhu J,Gaiha G D,John S P,Pertel T,Chin C R,Gao G,Qu H,Walker B D,Elledge S J,Brass A L.Reactivation of latent HIV-1by inhibition of BRD4[J].Cell Rep,2012,2(4):807-816.
[63]Bartholomeeusen K,Xiang Y,Fujinaga K,Peterlin B M.Bromodomain and extra-terminal(BET)bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b(PTEFb)from 7SK small nuclear ribonucleoprotein[J].J Biol Chem,2012,287(43):36609-36616.
[64]Boehm D,Calvanese V,Dar R D,Xing S,Schroeder S,Martins L,Aull K,Li P C,Planelles V,Bradner J E,Zhou M M,Siliciano R F,Weinberger L,Verdin E,Ott M.BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism[J].Cell Cycle,2013,12(3):452-462.
[65]Li Z,Guo J,Wu Y,Zhou Q.The BET bromodomain inhibitor JQ1activates HIV latency through antagonizing Brd4inhibition of Tat-transactivation[J].Nucleic Acids Res,2013,41(1):277-287.
[66]Banerjee C,Archin N,Michaels D,Belkina A C,Denis G V,Bradner J,Sebastiani P,Margolis D M,Montano M.BET bromodomain inhibition as a novel strategy for reactivation of HIV-1[J].J Leukoc Biol,2012,92(6):1147-1154.
[67]Lee D U,Katavolos P,Palanisamy G,Katewa A,Sioson C,Corpuz J,Pang J,DeMent K,Choo E,Ghilardi N,Diaz D,Danilenko D M.Nonselective inhibition of the epigenetic transcriptional regulator BET induces marked lymphoid and hematopoietic toxicity in mice[J].Toxicol Appl Pharmacol,2016,300(1):47-54.
[68]Gaudio E,Tarantelli C,Ponzoni M,Odore E,Rezai K,Bernasconi E,Cascione L,Rinaldi A,Stathis A,Riveiro E,Cvitkovic E,Zucca E,Bertoni F.Bromodomain inhibitor OTX015(MK-8628)combined with targeted agents shows strong in vivo antitumor activity in lymphoma[J].Oncotarget,2016,7(36):58142-58147.
[69]Lu P,Qu X,Shen Y,Jiang Z,Wang P,Zeng H,Ji H,Deng J,Yang X,Li X,Lu H,Zhu H.The BET inhibitor OTX015reactivates latent HIV-1through PTEFb[J].Sci Rep,2016,6(1):24100.
[70]Bouchat S,Delacourt N,Kula A,Darcis G,Van Driessche B,Corazza F,Gatot JS,Melard A,Vanhulle C,Kabeya K,Pardons M,Avettand-Fenoel V,Clumeck N,De Wit S,Rohr O,Rouzioux C,Van Lint C.Sequential treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1[J].EMBO Mol Med,2015,8(2):117-138.
[71]Clouser C L,Bonnac L,Mansky L M,Patterson S E.Characterization of permeability,stability and antiHIV-1activity of decitabine and gemcitabine divalerate prodrugs[J].Antivir Chem Chemother,2014,23(6):223-230.
[72]Fernandez G,Zeichner S L.Cell line-dependent variability in HIV activation employing DNMT inhibitors[J].Virol J,2010,7(1):266.
[73]Rawson J M,Daly M B,Xie J,Clouser C L,Landman S R,Reilly C S,Bonnac L,Kim B,Patterson S E,Mansky L M.5-Azacytidine Enhances the Mutagenesis of HIV-1by Reduction to 5-Aza-2'-Deoxycytidine[J].Antimicrob Agents Chemother,2016,60(4):2318-2325.
[74]Ding D,Qu X,Li L,Zhou X,Liu S,Lin S,Wang P,Liu S,Kong C,Wang X,Liu L,Zhu H.Involvement of histone methyltransferase GLP in HIV-1latency through catalysis of H3K9dimethylation[J].Virology,2013,440(2):182-189.
[75]Verma M.Epigenetic regulation of HIV,AIDS,and AIDS-related malignancies[J].Methods Mol Biol,2015,1238(1):381-403.
[76]Levy Y,Sereti I,Tambussi G,Routy J P,Lelievre J D,Delfraissy J F,Molina J M,Fischl M,Goujard C,Rodriguez B,Rouzioux C,Avettand-Fenoel V,Croughs T,Beq S,Morre M,Poulin J F,Sekaly R P,Thiebaut R,Lederman M M.Effects of recombinant human interleukin 7on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy:results of a phase I/IIa randomized,placebocontrolled,multicenter study[J].Clin Infect Dis,2012,55(2):291-300.
[77]Nunnari G,Pomerantz R J.IL-7as a potential therapy for HIV-1-infected individuals[J].Expert Opin Biol Ther,2005,5(11):1421-1426.
[78]Wang F X,Xu Y,Sullivan J,Souder E,Argyris E G,Acheampong E A,Fisher J,Sierra M,Thomson M M,Najera R,Frank I,Kulkosky J,Pomerantz R J,Nunnari G.IL-7is a potent and proviral strain-specific inducer of latent HIV-1cellular reservoirs of infected individuals on virally suppressive HAART[J].J Clin Invest,2005,115(1):128-137.
[79]Stellbrink H J,van Lunzen J,Westby M,O'Sullivan E,Schneider C,Adam A,Weitner L,Kuhlmann B,Hoffmann C,Fenske S,Aries P S,Degen O,Eggers C,Petersen H,Haag F,Horst H A,Dalhoff K,Mocklinghoff C,Cammack N,Tenner-Racz K,Racz P.Effects of interleukin-2plus highly active antiretroviral therapy on HIV-1replication and proviral DNA(COSMIC trial)[J].AIDS,2002,16(11):1479-1487.
[80]Badia R,Pujantell M,Riveira-Munoz E,Puig T,Torres-Torronteras J,Marti R,Clotet B,Ampudia RM,Vives-Pi M.The G1/S Specific Cyclin D2Is a Regulator of HIV-1 Restriction in Non-proliferating Cells[J/OL].PLoS Pathog,2016,12(8):e1005829.
[81]Xing S,Bullen C K,Shroff N S,Shan L,Yang H C,Manucci J L,Bhat S,Zhang H,Margolick J B,Quinn T C,Margolis D M,Siliciano J D,Siliciano R F.Disulfiram reactivates latent HIV-1in a Bcl-2-transduced primary CD4+T cell model without inducing global T cell activation[J].J Virol,2011,85(12):6060-6064.
[82]Doyon G,Zerbato J,Mellors J W,Sluis-Cremer N.Disulfiram reactivates latent HIV-1expression through depletion of the phosphatase and tensin homolog[J].Aids,2013,27(2):F7-f11.
[83]Elliott J H,McMahon J H,Chang C C,Lee S A,Hartogensis W,Bumpus N,Savic R,Roney J,Hoh R,Solomon A,Piatak M,Gorelick R J,Lifson J,Bacchetti P,Deeks S G,Lewin S R.Short-term administration of disulfiram for reversal of latent HIV infection:aphase 2dose-escalation study[J/OL].Lancet HIV,2015,2(12):e520-529.
[84]Spivak A M,Andrade A,Eisele E,Hoh R,Bacchetti P,Bumpus N N,Emad F,Buckheit R,3rd,McCanceKatz E F,Lai J,Kennedy M,Chander G,Siliciano R F,Siliciano J D,Deeks S G.A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy[J].Clin Infect Dis,2014,58(6):883-890.
[85]Li P,Kaiser P,Lampiris H W,Kim P,Yukl S A,Havlir D V,Greene W C,Wong J K.Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation[J].Nat Med,2016,22(7):807-811.
[86]Gallo R C.Shock and kill with caution[J].Science,2016,354(6309):177-178.